Not applicableApproved For MarketingNCT02437500
What this trial is testing
Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
Who this might be right for
Clostridioides Difficile Infection
Seres Therapeutics, Inc.